SANUWAVE Health, Inc. Common Stock logo

SANUWAVE Health, Inc. Common Stock(SNWV)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.82
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SNWV

11/13/2026: SNWV (1-star) is currently NOT-A-BUY. Pass it for now.

SANUWAVE Health, Inc. is a medical technology company specializing in noninvasive, directed-energy devices for advanced wound care. Its growth is primarily driven by the UltraMIST ultrasound system and a recurring revenue model from single-use consumables. While the company has achieved double-digit revenue growth and secured a Nasdaq listing, it faces significant execution and financial risks, including a recent delisting notice for failing market-value requirements. The investment story centers on the clinical potential of its PACE technology, yet the small-cap nature and lack of consistent profitability necessitate caution. The stock may best suit speculative investors who should closely monitor the company's efforts to regain Nasdaq compliance.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the company has shown revenue growth, execution risk and market valuation challenges make it speculative.
Momentum investorWeak fitThe stock has experienced downward pressure and high volatility, failing to provide a consistent positive upturn signal.
Value investorMixed fitDespite lower valuation multiples, the lack of consistent profitability limits the margin of safety.
Dividend investorWeak fitThe company does not pay a dividend and focuses on cash preservation for growth.
Low-risk investorWeak fitThe company's status as a small-cap, pre-profitability stock involves high volatility and execution risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall market capitalization and low liquidity lead to sharp price fluctuations.
Valuation riskHighThe market cap has fallen significantly, raising concerns about long-term stability and exchange compliance.
Competition risk (MedTech)Medium / highThe wound care sector is crowded with larger, more dominant players.
Business qualityMediumWhile the product line has clinical utility, the company remains in a growth phase with unproven profitability.
Dividend incomeLow / noneNo income generation is available for shareholders.
Execution riskHighSuccessful scaling and maintaining exchange listing status are critical hurdles.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 15.66M USD
Price to earnings Ratio -
1Y Target Price 40
Price to earnings Ratio -
1Y Target Price 40
Volume (30-day avg) 104.8K shares
Beta 1.48
52 Weeks Range 1.55 - 35.29
Updated Date 11/14/2026
52 Weeks Range 1.55 - 35.29
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.38

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -7.04%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SNWV receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
SNWV has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+137.7%) and solid revenue growth (+35.0%) are partially offset by soft cash generation (FCF margin 4.4%), modest insider ownership of 1.31%.

Financial Health Rating

★★★★★
SNWV's financial health is supported by solid cash strength, including free-cash-flow generation (4.4% of revenue). Operating efficiency is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SNWV's strongest growth driver at +137.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+35.0%, solid) is also solid, while free-cash-flow growth (-1.6%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 36.2% (moderate) and 71.9% of outstanding shares are publicly tradable (solid). Insider ownership of 1.31% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Solas Capital Management LLC 7.10%
Awm Investment Company Inc 5.28%
Praetorian PR LLC 4.59%
Vanguard Capital Management, LLC 4.10%
Opaleye Management Inc 3.56%

Unit Economics (Per $1K Revenue)

★★★★★
SNWV generates approximately $771 of gross profit, $112 of operating income, and $44 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and weak cash conversion support a 3-star rating, while capital efficiency is strong.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.72%

Quantitative Style Profile

★★★★★
SNWV has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical Device SystemsDirect sales of UltraMIST and dermaPACE systems to hospitals and clinics.The company makes money by selling specialized machines that treat chronic wounds.
ConsumablesSterile, single-use applicators required for each treatment.This is the core of their business; once a clinic buys a machine, they must keep buying supplies from the company.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-10
When After Market
Estimate 0.01
Actual -0.16

Profitability

Profit Margin 8.55%
Operating Margin (TTM) 1.29%

Management Effectiveness

Return on Assets (TTM) 0.97%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE 24.39
Enterprise Value 26.63M
Price to Sales(TTM) 0.38
Enterprise Value 26.63M
Price to Sales(TTM) 0.38
Enterprise Value to Revenue 0.64
Enterprise Value to EBITDA 3.39
Shares Outstanding 8.60M
Shares Floating 6.19M
Shares Outstanding 8.60M
Shares Floating 6.19M
Percent Insiders 1.31
Percent Institutions 36.19

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.